Watermann I[au] - Search Results

Year	Number of Results
2003	2
2006	1
2007	1
2014	2
2015	1
2017	1
2018	1
2021	1
2023	0

1

[CT-Screening for Lung Cancer - what is the Evidence?].

Watermann I, Reck M. Watermann I, et al. Dtsch Med Wochenschr. 2018 Apr;143(7):494-497. doi: 10.1055/s-0043-104919. Epub 2018 Apr 3. Dtsch Med Wochenschr. 2018. PMID: 29614540 German.

2

Identification of molecular signatures associated with early relapse after complete resection of lung adenocarcinomas.

Pasternack H, Kuempers C, Deng M, Watermann I, Olchers T, Kuehnel M, Jonigk D, Kugler C, Stellmacher F, Goldmann T, Kirfel J, Ammerpohl O, Perner S, Reck M. Pasternack H, et al. Among authors: watermann i. Sci Rep. 2021 May 5;11(1):9532. doi: 10.1038/s41598-021-89030-9. Sci Rep. 2021. PMID: 33953302 Free PMC article.

3

Activation of CD95L fusion protein prodrugs by tumor-associated proteases.

Watermann I, Gerspach J, Lehne M, Seufert J, Schneider B, Pfizenmaier K, Wajant H. Watermann I, et al. Cell Death Differ. 2007 Apr;14(4):765-74. doi: 10.1038/sj.cdd.4402051. Epub 2006 Oct 20. Cell Death Differ. 2007. PMID: 17053806

4

Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation?

Watermann I, Schmitt B, Stellmacher F, Müller J, Gaber R, Kugler Ch, Reinmuth N, Huber RM, Thomas M, Zabel P, Rabe KF, Jonigk D, Warth A, Vollmer E, Reck M, Goldmann T. Watermann I, et al. Diagn Pathol. 2015 Jul 28;10:130. doi: 10.1186/s13000-015-0362-5. Diagn Pathol. 2015. PMID: 26215852 Free PMC article.

5

Correlation of EGFR expression, gene copy number and clinicopathological status in NSCLC.

Gaber R, Watermann I, Kugler C, Reinmuth N, Huber RM, Schnabel PA, Vollmer E, Reck M, Goldmann T. Gaber R, et al. Among authors: watermann i. Diagn Pathol. 2014 Sep 17;9:165. doi: 10.1186/s13000-014-0165-0. Diagn Pathol. 2014. PMID: 25227424 Free PMC article.

6

Tumor-associated antigen profiling in breast and ovarian cancer: mRNA, protein or T cell recognition?

Kayser S, Watermann I, Rentzsch C, Weinschenk T, Wallwiener D, Gückel B. Kayser S, et al. Among authors: watermann i. J Cancer Res Clin Oncol. 2003 Jul;129(7):397-409. doi: 10.1007/s00432-003-0445-7. Epub 2003 Jun 26. J Cancer Res Clin Oncol. 2003. PMID: 12836015

7

[A reduced TKI dosage is not associated with loss of activity in EGFR mutated NSCLC patients].

Reinmuth N, Heigener D, Goldmann T, Watermann I, Reck M. Reinmuth N, et al. Among authors: watermann i. Pneumologie. 2014 Sep;68(9):619-23. doi: 10.1055/s-0034-1377927. Epub 2014 Sep 9. Pneumologie. 2014. PMID: 25203821 Free article. Clinical Trial. German.

8

Preselection of EGFR mutations in non-small-cell lung cancer patients by immunohistochemistry: comparison with DNA-sequencing, EGFR wild-type expression, gene copy number gain and clinicopathological data.

Gaber R, Watermann I, Kugler C, Vollmer E, Perner S, Reck M, Goldmann T. Gaber R, et al. Among authors: watermann i. Rom J Morphol Embryol. 2017;58(4):1175-1184. Rom J Morphol Embryol. 2017. PMID: 29556606 Free article.

9

Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells.

Rentzsch C, Kayser S, Stumm S, Watermann I, Walter S, Stevanoviç S, Wallwiener D, Gückel B. Rentzsch C, et al. Among authors: watermann i. Clin Cancer Res. 2003 Oct 1;9(12):4376-86. Clin Cancer Res. 2003. PMID: 14555509

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results